Revolutions Medical gets syringe production contract
Revolutions Medical said that the capacity can be increased to 20 million syringes per month, and shipments will begin by July 2011. The agreement extends the company’s relationship
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China.